HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Lisata Therapeutics (NASDAQ:LSTA) and maintained a price target of $15. This endorsement from a reputable analyst could influence investor sentiment and potentially impact the stock's short-term performance.
January 04, 2024 | 3:54 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lisata Therapeutics has been given a reiterated Buy rating and a $15 price target by HC Wainwright & Co. analyst Joseph Pantginis, which could positively influence the stock's short-term performance.
Analyst ratings, especially from established firms like HC Wainwright & Co., can significantly affect investor sentiment. A reiterated Buy rating and a maintained price target suggest confidence in the company's prospects, which can lead to increased investor interest and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100